Related Experiment Videos
[Immunochemotherapy of advanced bladder tumors]
1Clinique d'Urologie, Institut de Médecine, Sofüski, Bulgarie.
Journal D'Urologie
|January 1, 1989
Summary
This study explored intra-arterial chemotherapy combined with BCG immunotherapy for advanced bladder tumors. Preliminary results show satisfactory outcomes, suggesting potential for combined treatment strategies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Advanced bladder tumors (Stage T2-T4) pose treatment challenges.
- Patients included had contraindications or refused surgery.
- This study investigated a novel combination therapy approach.
Purpose:
- To evaluate the efficacy of intra-arterial chemotherapy combined with BCG bladder instillation for advanced bladder tumors.
- To assess treatment response, survival rates, and safety.
- To explore chemotherapy-immunotherapy combination as a treatment option.
Summary:
- Ten patients received intra-arterial chemotherapy (Cyclophosphamide, Farmorubicine, Biocisplatin) and BCG (Calgevax) instillation.
- Two patients showed very good response, one relapsed post-surgery but achieved remission.
- 40% had partial response; mean survival was 12.4 months with no disease activation.
Impact:
- Preliminary findings suggest satisfactory results for advanced bladder tumors.
- The combination therapy warrants further investigation in larger studies.
- This research opens avenues for combined chemotherapy and immunotherapy in bladder cancer treatment.